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measurers was 0.816 (p  0.0001). Cost/QALY exceeded cost/life-year in 61% of cases 
whereas cost/life-year exceeded cost/QALY in 39% of cases. In 124 (84%) of com-
parisons, both cost/QALY and cost/life-year ratios were below a pre-speciﬁed thresh-
old (e.g., $50,000 per QALY or life-year). In 14 (10%) of cases, adjusting for quality 
of life resulted in a ratio that crossed the $50,000 value, whereas in 4(3%) the cost/
QALY ratio crossed the $100,000 threshold. CONCLUSIONS: Adjusting life years 
for HRQL does not substantively affect cost per life year ratios for the vast majority 
of published cancer interventions in our sample. The results suggest that the method 
used for quality adjusting or even quality adjusting at all may not matter for cost-
effectiveness analyses of life saving cancer interventions. The results could differ for 
cancer interventions that have large impacts on patients’ HRQoL.
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OBJECTIVES: The assessment of economic implications, both for individualized 
breast cancer (BC) prevention and for public health policy, of ﬁndings concerning the 
risk of BC cancer in women with CHEK2 heterozygosity. METHODS: Cost-
 effectiveness analysis of genotyping every women at CHEK2 and offering—on the 
basis of her BC risk proﬁle—a personalized screening programme in which the starting 
age would vary, versus present strategy, was perfomed using modelling technique. 
Two scenarios were compared: (A) DNA CHEK2 test in all women, screening strategy 
beginning at 25 years of age only in CHEK2-positive women (1.2%) and standard 
screening strategy (beginning at 50 years) in the remained population; (B) without 
DNA CHEK2 test, in all women standard screening strategy. Data on life expectancy, 
BC risk, efﬁcacy of screening strategy and medical costs were obtained from published 
literatures. The cohort simulation started with 25-year-old women and projected 
direct medical costs and outcomes over patients lifetimes. Effectiveness was measured 
as life years gained (LYG). Only direct medical costs (BC screening and treatment) 
were included, assessed from health care payer perspective and reported in PLN (1 
EUR  4.5 PLN in 2009). 5% and 3.5% discount rate was used for cost and effective-
ness, respectively. RESULTS: The total lifetime costs/patient were estimated to be 
2223.85 PLN (discounted: 644.84 PLN) in (A) and 1998.20 PLN (discounted: 
430.15 PLN) in (B). The total LYG generated with scenario (A) were 50.958 vs. 
50,939 with scenario (B) (without discounting) and 23,170 vs. 23,165 (discounted), 
respectively. This results in ICER for (A) of 11,862 PLN/LYG (without discounting) 
and 41,865 PLN/LYG (discounted). Results were robust to sensitivity analyses. CON-
CLUSIONS: The use of CHEK2genotyping and pesonalized BC screening improves 
survival compared to standard strategy and considering the suggested threshold for 
cost-effectiveness in Poland (80,000 PLN/LYG in 2008), is cost-effective in the Polish 
health care system.
CN3
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OBJECTIVES: Sorafenib is an oral multi-kinase inhibitor that targets tumour cell 
proliferation and tumour angiogenesis. In the TARGET study (phase III trial), 
sorafenib plus best supportive care (BSC) signiﬁcantly prolonged progression-free 
survival (PFS) compared with BSC alone in patients with unresectable and/or meta-
static renal cell carcinoma (mRCC). The objective of this study was to assess the 
cost-effectiveness of sorafenib plus BSC versus BSC alone in mRCC patients in Turkey. 
The study was undertaken from a Turkish health care payer perspective. METHODS: 
A Markov model was developed to estimate costs and outcomes associated with 
sorafenib  BSC and BSC alone. The model tracked patients with mRCC through 
three health states: PFS, disease progression and death. PFS and survival were extrapo-
lated based on patient level trial data (TARGET) over a patients’ lifetime. Health 
effects were expressed as life years gained (LYG). Incidence of adverse events (AEs) 
were also obtained from TARGET. Resource utilization data were obtained via expert 
clinical opinion and included physician visits, hospitalizations, monitoring, treatment 
of AEs, etc. Unit costs were taken from the Social Security Institution’s ofﬁcial price 
list. Costs and effects were evaluated over a lifetime and discounted at 3%. Results 
were presented as incremental cost/LYG. Deterministic and probabilistic sensitivity 
analyses were also conducted. RESULTS: The incremental survival beneﬁt with 
sorafenib was 1.269 LYG. The lifetime cost per patient was 4,080 TL for BSC and 
47,665 TL for sorafenib  BSC. The incremental cost-effectiveness ratio of sorafenib 
 BSC was 34,342 TL per LYG compared with BSC alone. Sensitivity analyses con-
ﬁrmed the robustness of the model results. CONCLUSIONS: Compared with BSC 
alone, sorafenib  BSC is a cost-effective therapy option in the treatment of unresect-
able and/or metastatic renal cell carcinoma (mRCC) patients in Turkey.
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OBJECTIVES: To compare costs and health beneﬁts of two therapeutic options for 
the ﬁrst line treatment of chemotherapy naïve patients with locally advanced or meta-
static non-small cell lung cancer (NSCLC)—gemcitabin/cisplatin versus pemetrexed/
cisplatin. METHODS: A lifetime 3-week cycle Markov model was developed and 
adapted for Portugal in order to estimate costs per life year (LY) and per quality 
adjusted life year (QALY) gained for patients with adenocarcinoma and large cell car-
cinoma histology. The model considers three disease states—stable, response, progres-
sion—and two treatment phases—during and after ﬁrst line treatment. Patients may 
suffer from adverse events such as neutropenia and febrile neutropenia; fatigue; diar-
rhoea; nausea and vomiting; bleeding; anaemia; and thrombocytopenia. The clinical 
inputs to the economic model were obtained from phase 3 pivotal trial. Direct medical 
costs were estimated according to both the Society’s and the NHS perspectives. 
A Delphi panel was conducted in order to estimate resource consumption. Unit costs 
were derived from ofﬁcial sources. RESULTS: Patients treated with pemetrexed 
have a discounted expected LY 1.226 compared to 1.104 of those treated with gem-
citabine. Due to the low quality of life of the population considered, QALY are 0.655 
and 0.595, respectively. Incremental costs with pemetrexed are below a3,900 for both 
perspectives due to its higher price and to a larger consumption of best supportive care. 
Therefore, the incremental cost per LY gained is a31,154 for the Society (a63,859 per 
QALY) and a30,950a for the NHS (a63,441a per QALY). Sensitivity analysis shows 
that these ﬁndings are only affected by the assumptions adopted on the mean body 
surface area, drug wastage and overall survival. CONCLUSIONS: The incremental 
cost per LY of pemetrexed is acceptable. However, the incremental cost per QALY is 
higher than usual thresholds due to the low basal quality of life of the population.
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OBJECTIVES: The aim of this study is to evaluate general practitioners’ prescription 
(GPs) of different Proton Pump Inhibitors (PPIs) in the period between 2005 to 2008. 
METHODS: Analysis has been performed on a database of 99 medical practitioners 
that have managed an average of 150.000 inhabitants. We evaluate the PPIs prescrip-
tions from January 2005 to December 2008. Evaluations performed are the following: 
1) PPI prescription (total and separately for lansoprazole, esomeprazole, pantoprazole, 
rabeprazole, and omeprazole); 2) prevalence of the reimbursement purpose (Gastro-
protection—G; Acid-Related Disease—ARD); 3) prevalence of patients with ARD 
categorized on the basis of PPI prescriptions as drugs box/year (1–3 short treat-
ment—ST; 4–11 long treatment—LT; 12 very long treatment—VLT). Data were 
expressed as Compound Annual Growth Rate (CAGR). RESULTS: The total volume 
of PPI’s prescribing increased progressively over the 4 years (CAGR 15%). The 
growth for each molecule was: L 42%; E 11%; P 16; R 3%; O 1%. The reim-
bursement purpose was signiﬁcantly higher for G (CAGR 41%) than for ARD 
(CAGR 6%; p  0.01). We found an increase of ARD patients with VLT with a sig-
niﬁcant highest CAGR (ST 3.9%, LT 4.8%, VLT 7.4%; p  0.01). PPI prescription 
showed a highest CAGR for L in all patients (27%), while the lowest one was for O 
in VLT patients (-9%). CONCLUSIONS: Generic PPIs has unexpectedly increased the 
prescription of whole drug class during the period 2005–2008. We observed a marked 
increase in a very long duration PPI treatment for ARD that caused a relevant resource 
consumption. Our data suggest that the appropriateness of PPI prescription after 
generic PPI introduction should be carefully monitored to distinguish between cost-
effective from cost-ineffective PPI treatment.
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HAVE RECENT PHARMACEUTICAL REFORMS DAMAGED R&D?
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OBJECTIVES: To estimate the impact of cost-containment reforms on R&D indica-
tors of pharmaceutical ﬁrms in eight countries and draw policy recommendations. 
METHODS: The average treatment effect on the treated is econometrically estimated 
with difference-in-difference (DiD); before-after comparisons; DiD with correlated 
random trend and a synthetic control group; kernel and nearest neighbour matching 
DiD methods. RESULTS: This study estimates short-term effects of recent regulatory 
changes in public health care on ﬁnancial indicators related to pharmaceutical R&D 
in Denmark, France, Germany, Italy, Japan, Norway, Sweden, and the US. The dataset 
represents a panel of ﬁnancial statements of 1306 pharmaceutical ﬁrms for the period 
1997–2007. The evaluated indicators include R&D expenditure, R&D expenditure 
to total revenue, cash ﬂow, gross margin, and price-to-book ratio. The national 
pharmaceutical expenditures, population, availability of credit for the private sector, 
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levels (6 studies) and greater proportions of patients achieving LDL goals (5 studies). 
CONCLUSIONS: Policy-driven programs that encourage wide-spread switching of 
statins without consideration of patient-speciﬁc circumstances may impact the delivery 
of patient care and treatment outcomes.
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OBJECTIVES: To determine the effect of an employer-sponsored pharmacist-provided 
medication therapy management program (MTMP) on clinical outcomes and social 
measures in patients with hypertension. METHODS: A prospective, intent-to-treat, 
pre-post longitudinal study. Patients were Lucas County employees and/ dependents 
with a diagnosis for hypertension. The face-to-face MTMP was provided by pharma-
cists from the Toledo Area Coalition of Independent Pharmacies at seven pharmacies. 
JNC-VII guidelines were used to design interventions and set patient goals. Interven-
tions were provided every six months. Information recorded included demographic 
information, clinical markers and social measures. Data was documented by pharma-
cists or pharmacy technicians using intake forms. Data was analyzed using SPSSv 16.0 
for two groups i.e. hypertension only (may have other comorbid conditions excluding 
diabetes) and hypertensive diabetics. Wilcoxon signed-rank test was used to compare 
2 time points and the Friedman test was to compare readings at baseline, six and 12 
months. RESULTS: Two hundred and twenty eight patients have enrolled in the 
program. For the hypertension only group, mean systolic blood pressure (SBP) 
improved from 133.73 o 17.36 to 130.86 o 16.49 (p  0.112). For uncontrolled 
hypertensive patients in this group, mean SBP improved from 152.54 o 11.80 to 
139.77 o 18.22 (p  0.000). Diastolic blood pressure improved from 99.330 to 91.50 
(p  0.049). For hypertensive diabetic patients mean SBP decreased from 135.64 o 
18.21 to 127.55 o 15.26 (p  0.003). Signiﬁcant decrease was also observed for 
hypertensive diabetic with uncontrolled blood pressure at baseline (146.26 o 13.55 to 
131.44 o 13.66 mmHg; p  0.000). Mean alcohol and caffeine consumption decreased 
non-signiﬁcantly for patients in both groups. CONCLUSIONS: Pharmacists interven-
tions assisted uncontrolled patients in reaching their goal BP reading, and for con-
trolled patients, helped in maintaining their level of control. Periodic monitoring by 
a pharmacist can assist patients in reaching their targeted goal and maintaining that 
value so as to prevent long-term complications and costs.
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OBJECTIVES: African American men have lower hypertension control rates and 
higher cardiovascular disease mortality rates than those of Caucasian males. We 
examined how a peer approach to hypertension management could improve blood 
pressure control for participants, mostly minority males. METHODS: This is a longi-
tudinal cohort study. Patients in the intervention group enrolled relatives or friends 
in the hypertension education program and attended as teams, the monthly education 
sessions. Patients in the control group followed standard of care. Blood pressure was 
taken by a nurse, at baseline and every 3 months, for up to 15 months. Other clinical 
and behavioral information was obtained from medical charts and surveys at baseline 
and follow-up visits. We used survival analysis to compare time to achieve the deﬁned 
goal (patients without diabetes: systolic blood pressure (SBP)  140, patients with 
diabetes: SBP  130) between the two groups controlling for confounders and clusters 
of patients. RESULTS: A total of 250 subjects were included in the study; half in the 
intervention group. Approximately 90% of the participants were African American 
and 60% were males. The baseline blood pressure levels were 149/88 mmHg and 
146/88 mmHg in the control and intervention group (p  0.25). After controlling 
baseline blood pressure, gender, race, age, diabetes, smoking and patient clusters, we 
found that patients in the intervention group reached goal at a rate 4.97 times (95% 
CI: 2.02–12.25) higher than the rate in the control group. However, higher baseline 
SBP (HR  0.96, 95% CI: 0.93–0.98), males (HR  0.54, 95% CI: 0.31–0.95) and 
smoking (HR  0.39, 95% CI: 0.20–0.77) were signiﬁcantly associated with longer 
time to achieve the goal. CONCLUSIONS: Patients who approached hypertension 
management with their peers were much more likely to achieve blood pressure control 
in a shorter time than patients in standard of care. These ﬁndings have implications 
for clinical and public health interventions.
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OBJECTIVES: In 2004 and 2005, Menzis, a Dutch health insurance, company stimu-
lated physicians in prescribing cheaper versions of statins and proton pump inhibitors 
by offering ﬁnancial incentives to physicians who could reach speciﬁc annual prescrib-
ing thresholds (preference policy). The objective of this research is to quantify the 
effect of the preference policy of Menzis on the utilization/demand of statins in the 
Northern part of The Netherlands. Furthermore, we test the hypothesis of a signiﬁcant 
difference in the increase of simvastatin starters between Menzis and the other insur-
ance companies potentially due to the preference policy. METHODS: Prescription 
data originating from the Northern The Netherlands on the amount of simvastatin 
starters and simvastatin market share were extracted from IADB.nl, an in-house pre-
scription database of the University of Groningen. State-space analysis was used in 
order to estimate the effect of the preference policy. The Kalman ﬁlter was applied on 
an intervention state space model, followed by diagnostic tests for the independence, 
homoscedasticity and normality of the standardized prediction errors. RESULTS: A 
sharp increase in the level as well as in the trend of the market share of simvastatin 
around the last trimester of 2004 was observed, corresponding to the time point when 
the preference policy was initiated. A steep increase was apparent also on both the 
amount of Menzis clients that started use of simvastatin, as well as on the market 
share of simvastatin among Menzis clients. The interventions had a signiﬁcant, 
decreasing effect on the cost of simvastatin treatment. CONCLUSIONS: The prefer-
ence policy resulted in an increase of prescribing for simvastatin, the cheaper statin 
alternative, which consequently resulted in a decrease in cholesterol lowering treat-
ment costs.
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OBJECTIVES: In 2006, US Medicare created a new drug beneﬁt (Part D) for older 
adults. Part D cut down the number of older adults lacking drug coverage and reduced 
out-of-pocket costs, yet little is known about its effect on treatment of speciﬁc condi-
tions. Given Medicare’s role in ﬁnancing 20% of US and 9% of global pharmaceutical 
expenditures it is important to evaluate its effects. We examined Part D’s effect on 
drug utilization for congestive heart failure (CHF), a condition with substantial mor-
bidity and mortality. METHODS: Quasi-experimental study using insurance claims 
data from 7201 older adults with CHF continuously enrolled in a Medicare plan in 
2004–07. Three intervention groups with either no or limited drug coverage in 2004–
05 (US$600 or US$1400 annual limits) who obtained Part D drug beneﬁts in 2006 
were compared with a group with generous pharmacy beneﬁts throughout 2004–07. 
We estimated Part D’s effect on CHF drug utilization and adherence, adjusting 
for differences in sociodemographic and health status measures. RESULTS: Part D 
was associated with a 37% (95% CI 31–43%) increase in CHF prescriptions ﬁlled by 
the group previously lacking coverage, and increases of 10% (95% CI 6–12) and 7% 
(95% CI 6–8%) in the groups with limited prior coverage, relative to comparison 
group. The group previously lacking coverage was more likely to be adherent to 
angiotensin-converting enzyme inhibitors (ratio of odds ratios 2.20, 95% CI 1.65–
2.88) and beta blockers (ratio of odds ratios 2.56, 95% CI 1.95–3.35) after Part D 
relative to comparison group. Groups with limited prior drug coverage experienced 
statistically signiﬁcant, if smaller, improvements in adherence. CONCLUSIONS: 
Medicare Part D was associated with signiﬁcant improvements in adherence to phar-
macotherapy for CHF, the magnitude of which varied with the level of prior drug 
coverage. These ﬁndings have implications for health systems contemplating drug 
coverage expansions.
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OBJECTIVES: Market concentration of products affects competition, and thus is a 
key concern of marketing ﬁrms, policy makers, and regulators. Angiotensin converting 
enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers(ARBs) are two 
classes of hypertensive drugs, competing for one of the largest and most proﬁtable 
pharmaceutical market in the US. However, little is known about how market con-
centration affects the consumption of these drugs. We sought to measure the concen-
tration of drugs in ACE inhibitors and ARBs and its association with their relative 
market share. METHODS: We used the State Drug Use Data from the Medicaid Drug 
Rebate Program that provides prescription drugs to 46 million low-income Americans. 
We linked the data with the WHO Collaborating Centre for Drug Statistics Methodol-
ogy to obtain Deﬁned Daily Dose (DDD) measurements for drug consumption for 
four large states, for a total of 16 quarters of continuous measurements between 2005 
and 2008. We used a Herﬁndahl-Hirschman Index (HHI) to measure the concentra-
tion in ACE inhibitors and ARBs, by DDD and reimbursements. We conducted mul-
tivariate GLS regression analysis by regressing the HHI on the relative market share 
of ACE inhibitors, adjusted for time trend, the interaction between the HHI and time 
trend, and random effects of states. RESULTS: During the 16 quarters between 2005 
and 2008, the mean concentration index for ACE Inhibitors was 339 (s.d. 71) by 
DDD, 442 (s.d. 148) by reimbursements, and for ARBs 887 (s.d. 277), 693 (s.d. 227) 
by DDD and reimbursements, respectively. The market share of ACE inhibitors was 
negatively associated with the concentration in ARBs (p  0.001, p  0.001), and 
marginally positively associated with the concentration in ACE inhibitors (p  0.05, 
p  0.09), by DDD and reimbursements, respectively. CONCLUSIONS: The relative 
market share of ACE inhibitors and ARBs is cross-linked with concentration of drugs 
within each of these two classes.
